ムラガキ ヨシヒロ   MURAGAKI Yoshihiro
  村垣 善浩
   所属   研究施設 研究施設
   職種   教授
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Role of photodynamic therapy using talaporfin sodium and a semiconductor laser in patients with newly diagnosed glioblastoma.
掲載誌名 正式名:Journal of neurosurgery
略  称:J Neurosurg
ISSNコード:(1933-0693)0022-3085(Linking)
掲載区分国外
巻・号・頁 131(5),1361-1368頁
著者・共著者 NITTA Masayuki†, MURAGAKI Yoshihiro*, MARUYAMA Takashi, ISEKI Hiroshi, KOMORI Takashi, IKUTA Soko, SAITO Taiichi, YASUDA Takayuki, HOSONO Junji, OKAMOTO Saori, KORIYAMA Shunichi, KAWAMATA Takakazu
発行年月 2019/11
概要 OBJECTIVEIn this study on the effectiveness and safety of photodynamic therapy (PDT) using talaporfin sodium and a semiconductor laser, the long-term follow-up results of 11 patients with glioblastoma enrolled in the authors' previous phase II clinical trial (March 2009-2012) and the clinical results of 19 consecutive patients with newly diagnosed glioblastoma prospectively enrolled in a postmarket surveillance (March 2014-December 2016) were analyzed and compared with those of 164 patients treated without PDT during the same period.METHODSThe main outcome measures were the median overall survival (OS) and progression-free survival (PFS) times. Moreover, the adverse events and radiological changes after PDT, as well as the patterns of recurrence, were analyzed and compared between the groups. Kaplan-Meier curves were created to assess the differences in OS and PFS between the groups. Univariate and multivariate analyses were performed to identify the prognostic factors, including PDT, among patients with newly diagnosed glioblastoma.RESULTSThe median PFS times of the PDT and control groups were 19.6 and 9.0 months, with 6-month PFS rates of 86.3% and 64.9%, respectively (p = 0.016). The median OS times were 27.4 and 22.1 months, with 1-year OS rates of 95.7% and 72.5%, respectively (p = 0.0327).
DOI 10.3171/2018.7.JNS18422
PMID 30544336